Spyre Therapeutics, Inc. SYRE Payment For Deferred Offering Costs
Payment For Deferred Offering Costs at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept syre:PaymentForDeferredOfferingCosts.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s payment for deferred offering costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s payment for deferred offering costs?
- Spyre Therapeutics, Inc. (SYRE) reported payment for deferred offering costs of $171K in Q1 2026.
- How has Spyre Therapeutics, Inc.'s payment for deferred offering costs changed year-over-year?
- Spyre Therapeutics, Inc.'s payment for deferred offering costs increased by 83.9% year-over-year, from $93K to $171K.
- What does payment for deferred offering costs mean?
- This represents the cash paid for legal, accounting, and underwriting fees associated with future or pending equity offerings. These costs are capitalized and subsequently offset against the proceeds of the offering.